{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T11:05:10Z","timestamp":1779966310220,"version":"3.53.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This case series reports three patients with active ulcerative colitis (UC) successfully treated with mirikizumab, a selective IL-23p19 monoclonal antibody. Mirikizumab was initiated based on both clinical presentation and a histopathological marker\u2014high neutrophilic infiltration of the colonic epithelium classified as Geboes Grade 3.2\u2014which reflects an IL-23\/Th17-driven inflammatory phenotype. The cases included: an elderly man with acute severe pancolitis and primary nonresponse to infliximab; a middle-aged woman with steroid-dependent left-sided UC and inadequate response to adalimumab and ustekinumab; and a young biologic-na\u00efve woman with steroid-refractory UC and bowel urgency. All three patients demonstrated high epithelial neutrophilic infiltration (Geboes Grade 3.2). These cases demonstrate the potential utility of histology-guided biologic selection and support Geboes Grade 3.2 as a candidate predictive biomarker for IL-23 inhibitor response in UC.<\/jats:p>","DOI":"10.1007\/s12328-026-02298-0","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T12:39:35Z","timestamp":1772800775000},"page":"505-508","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Histopathological predictor of response to mirikizumab in active ulcerative colitis"],"prefix":"10.1007","volume":"19","author":[{"given":"Ichitaro","family":"Horiuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3610-1025","authenticated-orcid":false,"given":"Akira","family":"Horiuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Horiuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"2298_CR1","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1053\/j.gastro.2024.10.001","volume":"167","author":"S Singh","year":"2024","unstructured":"Singh S, Loftus EV Jr, Limketkai BN, et al. AGA Clinical Guidelines Committee. AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis. Gastroenterology. 2024;167:1307\u201343.","journal-title":"Gastroenterology"},{"key":"2298_CR2","doi-asserted-by":"publisher","first-page":"5180","DOI":"10.3390\/jcm14155180","volume":"14","author":"S Ukai","year":"2025","unstructured":"Ukai S, Horiuchi I, Terashima T, et al. Assessment of ulcerative colitis patients with elevated neutrophilic infiltration in the colonic mucosal epithelium using the Komagane subclassification of the Geboes score Grade 3. J Clin Med. 2025;14:5180.","journal-title":"J Clin Med"},{"key":"2298_CR3","doi-asserted-by":"publisher","first-page":"7214","DOI":"10.3390\/jcm14207214","volume":"14","author":"I Horiuchi","year":"2025","unstructured":"Horiuchi I, Horiuchi A, Horiuchi K, et al. Geboes histopathology score grade 3 subclassification predicts treatment response in active ulcerative colitis. J Clin Med. 2025;14:7214.","journal-title":"J Clin Med"},{"key":"2298_CR4","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1136\/gut.47.3.404","volume":"47","author":"K Geboes","year":"2000","unstructured":"Geboes K, Riddell R, Ost A, et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut. 2000;47:404\u20139.","journal-title":"Gut"},{"key":"2298_CR5","doi-asserted-by":"publisher","first-page":"5820","DOI":"10.1038\/s41467-022-33331-8","volume":"13","author":"P Pavlidis","year":"2022","unstructured":"Pavlidis P, Tsakmaki A, Pantazi E, et al. Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapy. Nat Commun. 2022;13:5820.","journal-title":"Nat Commun"},{"key":"2298_CR6","doi-asserted-by":"publisher","first-page":"ii64","DOI":"10.1093\/ecco-jcc\/jjab185","volume":"16","author":"TL Parigi","year":"2022","unstructured":"Parigi TL, Lacucci M, Ghosh S. Blockade of IL-23: What is in the pipeline? J Crohn Colitis. 2022;16:ii64\u201372.","journal-title":"J Crohn Colitis"},{"key":"2298_CR7","doi-asserted-by":"publisher","first-page":"e00578","DOI":"10.14309\/ctg.0000000000000578","volume":"14","author":"B Steere","year":"2023","unstructured":"Steere B, Schmitz J, Powell N, et al. Mirikizumab regulates genes involved in ulcerative colitis disease activity and anti-TNF resistance: results from a Phase 2 study. Clin Transl Gastroenterol. 2023;14:e00578.","journal-title":"Clin Transl Gastroenterol"},{"key":"2298_CR8","doi-asserted-by":"publisher","first-page":"4775","DOI":"10.3390\/ijms26104775","volume":"26","author":"P Pastras","year":"2025","unstructured":"Pastras P, Aggeletopoulou I, Papantoniou K, et al. Targeting the IL-23 receptor gene: a promising approach in inflammatory bowel disease treatment. Int J Mol Sci. 2025;26:4775.","journal-title":"Int J Mol Sci"},{"key":"2298_CR9","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","volume":"388","author":"G D\u2019Haens","year":"2023","unstructured":"D\u2019Haens G, Dubinsky M, Kobayashi T, et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2023;388:2444\u201355.","journal-title":"N Engl J Med"},{"key":"2298_CR10","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1093\/ecco-jcc\/jjad050","volume":"17","author":"F Magro","year":"2023","unstructured":"Magro F, Pai R, Kobayashi T, et al. Resolving histological inflammation in ulcerative colitis with mirikizumab in the LUCENT induction and maintenance trial programmes. J Crohns Colitis. 2023;17:1457\u201370.","journal-title":"J Crohns Colitis"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-026-02298-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-026-02298-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-026-02298-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T10:22:50Z","timestamp":1779963770000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-026-02298-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2298"],"URL":"https:\/\/doi.org\/10.1007\/s12328-026-02298-0","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"16 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human\/animal rights"}},{"value":"Informed consent was obtained from all patients to be included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}